Biosimilars

Affordable access to life-saving biologic therapies through high-quality biosimilar development

Biosimilar Development Excellence

Oracle BioTech develops high-quality, cost-effective biosimilars that provide patients with affordable access to essential biologic therapies across oncology, immunology, and other therapeutic areas.

Biosimilar Development

Oncology Biosimilars

Developing biosimilar versions of leading cancer treatments including monoclonal antibodies and targeted therapies.

  • Monoclonal antibody biosimilars
  • Targeted therapy alternatives
  • Immunotherapy biosimilars
  • Cost-effective cancer care
Learn More
Immunology Biosimilars

Immunology & Rheumatology

Biosimilar development for autoimmune conditions including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.

  • TNF-alpha inhibitor biosimilars
  • Interleukin inhibitor alternatives
  • Autoimmune disease treatments
  • Improved patient access
Learn More

Biosimilar Pipeline

Development

6 Programs

Analytical and functional characterization studies.

Preclinical

4 Programs

Comparability studies and toxicology assessment.

Phase I

3 Programs

Pharmacokinetic and safety comparability studies.

Phase III

2 Programs

Confirmatory efficacy and safety studies.

Approved

3 Products

Successfully approved and commercialized biosimilars.